COL18A1 and non-small cell lung carcinoma: In 2005, a novel recombinant human endostatin, Recombinant Human Endostatin Injection (trade name: Endostar; code name: YH-16), was approved by China’s State Food and Drug Administration (SFDA) for the treatment of NSCLC [5].